Iroko Pharma Announces Addl. International Licensing Deal For ZORVOLEX

(RTTNews) - Iroko Pharmaceuticals Inc. announced the initiation of a licensing agreement with Litha Pharma Proprietary Limited, a subsidiary of Litha Healthcare Group for the exclusive rights to market and sell ZORVOLEX (diclofenac) capsules in specified countries in East and Southern Africa.

Litha Healthcare Group, an operating company of Endo International plc (ENDP, ENL.TO), will be responsible for obtaining regulatory and pricing approval as well as provide marketing and distribution in countries including Angola, Botswana, Lesotho, Madagascar, Malawi, Mauritius, Mozambique, Namibia, Republic of South Africa, Seychelles, Swaziland, Tanzania and Zambia.

ZORVOLEX is approved by the United States Food and Drug Administration for the management of mild to moderate acute pain and osteoarthritis pain, and is available at pharmacies across the United States. ZORVOLEX was also recently approved by the Republic of Lebanon Ministry of Public Health (MOPH) for these indications.

Current licensing agreements for ZORVOLEX cover countries in the Middle East North Africa (MENA) region, Australia and New Zealand, Indonesia, and countries in Latin America, including the Central America region, Colombia, Venezuela, Mexico and Brazil.

Iroko is in discussions with additional potential distribution and marketing partners in other international markets. Iroko Pharmaceuticals, LLC, an affiliate of Iroko Pharmaceuticals Inc., will continue to retain all marketing rights to ZORVOLEX in the U.S.